Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
May 08, 2018 06:00 ET
|
Cellular Biomedicine Group Inc.
China Food and Drug Administration Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19 CAR-T Therapy Targeting NHL and ALLPositive 48-Week Phase I Clinical Data of...
Cellular Biomedicine Group Announces Results of 2018 Annual Meeting of Stockholders
April 30, 2018 08:30 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders
March 23, 2018 07:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
CBMG异体脂肪间充质祖细胞制剂AlloJoin™治疗膝骨关节炎I期临床试验获得初步的安全和有效性结果
March 21, 2018 09:10 ET
|
Cellular Biomedicine Group Inc.
中国上海市与加州库伯提诺市, March 21, 2018 (GLOBE NEWSWIRE) -- 西比曼生物科技集团（NASDAQ:CBMG，简称“CBMG”或“公司”） 是一家从事癌症免疫疗法和退行性疾病干细胞疗法开发的临床阶段生物制药公司。于中国杭州举办的“纳斯达克创新医药企业中国峰会暨杭州CBD论坛（CHIPS2018）”上，西比曼生物科技集团（CBMG）公司干细胞事业部（Stem...
Cellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin™ Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I Trial
March 16, 2018 07:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis
March 14, 2018 07:30 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group Reports Full-Year 2017 Financial Results and Recent Operational Progress
March 06, 2018 09:27 ET
|
Cellular Biomedicine Group Inc.
Expanded GMP manufacturing capacity to become one of the largest in-house CAR-T manufacturers amongst leading global biopharmaceutical companiesSigned partnerships with GE Healthcare Life Sciences...
Cellular Biomedicine Group Invited to Present a Keynote Speech at Phar-East Asia Pharma & Biotech Festival
March 01, 2018 09:15 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces $30.6 million Investment from Sailing Capital Overseas Investment Ltd.
February 05, 2018 08:18 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the development...
CBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish Solution
January 19, 2018 20:43 ET
|
Cellular Biomedicine Group Inc.
GE supports CBMG in its aim to speed up manufacturing timelines for its CAR T-cell therapy clinical trials and future commercializationFirst GE Healthcare FlexFactory™ for cell therapy installation in...